# US 2002/0160945 A1 · Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0160945 A1
- Document ID: US20020160945A1
- Status: Published application
- Kind: A1
- Application number: 09/928,047
- Filed: 2001-08-10
- Published: 2002-10-31
- Earliest claimed: 2000-08-10
- Assignees: Scantibodies Laboratory, Inc.
- Inventors: Thomas L. Cantor
- Web page: https://patentgrep.com/patent/US20020160945A1

## CPC

- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61K 38/1709: {from mammals}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a novel method for treating a patient that has osteoporosis and the patient may be having administered cyclase activating parathyroid hormone (CAP) or analogues. The patient receives an administration of a cyclase inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from between (SEQ ID No.1 [PTH2-84]) and (SEQ ID No. 2 [PTH34-84]), (preferably (SEQ ID No.3 [PTH3-84]) and (SEQ ID No. 4 [PTH28-84])), or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP, and yet, through a CAP rebound effect, is effective in itself in the treatment of osteoporosis.

## Claims

### Claim 1

A method for treating a patient that has osteoporosis and is being administered cyclase activating parathyroid hormone (CAP) or analogues thereof comprising also administering a cyclase inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from between (SEQ ID No.1 [PTH2-84]) and (SEQ ID No. 2 [PTH34-84]) or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP.

### Claim 2 (depends on 1)

The method of claim 1 wherein the peptide has an amino acid sequence from between (SEQ ID No.3 [PTH3-84]) and (SEQ ID No. 4 [PTH28-84])

### Claim 3 (depends on 1)

The method of claim 1 wherein one determines the amount of CAP and CIP present in the patient.

### Claim 4 (depends on 3)

The method of claim 3 wherein the CIP administration is performed in a pulsatile manner.

### Claim 5

A method for treating a patient that has osteoporosis comprising administering a cyclase inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from between (SEQ ID No.1 [PTH2-84]) and (SEQ ID No. 2 [PTH34-84]) or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP.

### Claim 6 (depends on 5)

The method of claim 5 wherein the peptide has an amino acid sequence from between (SEQ ID No.3 [PTH3-84]) and (SEQ ID No. 4 [PTH28-84])

### Claim 7 (depends on 5)

The method of claim 5 wherein one determines the amount of CAP and CIP present in the patient.

### Claim 8 (depends on 7)

The method of claim 7 wherein the CIP administration is performed in a pulsatile manner.
